New Weight Loss Drug Shows 'Remarkable' Results in Clinical Trials

Eli Lilly's drug tirzepatide helped patients lose up to 34 pounds on average, or 16% of their body weight, in clinical trials.
The drug is currently approved for Type 2 diabetes but now also shows promise as a weight loss aid, prompting Lilly to apply for FDA approval in the coming weeks.
In trials, 86% of patients lost at least 5% of their body weight on the highest dosage, compared to 30% of those on a placebo.
Tirzepatide could become the most effective anti-obesity drug to date, with annual sales potentially topping $50 billion.
The drug works by mimicking hormones that signal satiety, suppressing appetite; side effects can include nausea, diarrhea, and decreased blood sugar.